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ABSTRACT
Background We aimed to assess the impact of genomic 
human leukocyte antigen (HLA)- I/II homozygosity on 
the survival benefit of patients with unresectable locally 
advanced, metastatic non- small lung cancer treated 
by single- agent programmed cell death protein-1/
programmed death ligand 1 (PD1/PDL1) inhibitors.
Methods We collected blood from 170 patients with 
advanced lung cancer treated with immunotherapy at two 
major oncology centers in Western Australia. Genomic DNA 
was extracted from white blood cells and used for HLA- I/
II high- resolution typing. HLA- I/II homozygosity was tested 
for association with survival outcomes. Univariable and 
multivariable Cox regression models were constructed to 
determine whether HLA homozygosity was an independent 
prognostic factor affecting Overall Survival (OS) and 
Progression Free Survival (PFS). We also investigated the 
association between individual HLA- A and -B supertypes 
with OS.
Results Homozygosity at HLA- I loci, but not HLA- II, was 
significantly associated with shorter OS (HR=2.17, 95% CI 
1.13 to 4.17, p=0.02) in both univariable and multivariable 
analysis. The effect of HLA- I homozygosity in OS was 
particularly relevant for patients with tumors expressing 
PDL1 ≥50% (HR=3.93, 95% CI 1.30 to 11.85, p<0.001). 
The adverse effect of HLA- I homozygosity on PFS was only 
apparent after controlling for interactions between PDL1 
status and HLA- I genotype (HR=2.21, 95% CI 1.04 to 4.70, 
p=0.038). The presence of HLA- A02 supertype was the 
only HLA- I supertype to be associated with improved OS 
(HR=0.56, 95% CI 0.34 to 0.93, p=0.023).
Conclusion Our results suggest that homozygosity at ≥1 
HLA- I loci is associated with short OS and PFS in patients 
with advanced non- small cell lung cancer with PDL1 
≥50% treated with single- agent immunotherapy. Carriers 
of HLA- A02 supertype reported better survival outcomes in 
this cohort of patients.
BACKGROUND
Lung cancer is the second most common 
cancer worldwide in 2019 and the leading 
cancer- related cause of death among both 
men and women.1 While the introduction 
of immunotherapy into the treatment of 
advanced and metastatic non- small cell lung 
cancer (NSCLC) has improved survival when 
compared with chemotherapy, the 5 years 
survival rate continues to be as low as 23.2% 
and 15.5% in the first- line and second- line 
setting, respectively.2 While programmed 
death ligand (PDL1) expression on tumor 
cells is to date the only FDA (Food and 
Drug Administration) approved biomarker 
of response to anti- programmed cell death 
protein-1/programmed death ligand 1 (PD1/
PDL1) therapies, the 3- year and 5- year survival 
remains suboptimal even in patients with 
PDL1 expression on more than 50% of the 
viable tumor cells, that is, their tumor propor-
tion score (TPS) is ≥50%.2 3 Therefore, tumor 
PDL1 expression cannot be used as the only 
biomarker to predict response and survival in 
patients treated with anti- PD1/PDL1 therapy. 
There is ongoing research to identify afford-
able and easily obtained biomarkers that can 
be used as adjunct to tumor PDL1 expression 
for precision medicine.
Human leukocyte antigen (HLA) is 
expressed on somatic as well as immune 
cells. HLA molecules introduce internally 
processed cellular antigens to T lympho-
cytes to trigger a series of signals to activate 
or inhibit T cell proliferation and differenti-
ation.4 5 HLA molecules are divided into two 
types, HLA- I and HLA- II. HLA- I is expressed 
on all nucleated cells, including somatic, 
cancer and immune cells and presents cell 
peptides to activate CD8+T cells. HLA- II, 
on the other hand, is expressed on antigen- 
presenting cells and mediates the activation of 
CD4+ helper or regulatory T cells. HLA mole-
cules are encoded by the HLA gene complex 
located on the short arm of chromosome 6 at 
locus 21 (6p21).6 7 The HLA locus is not only 
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each locus having multiple alleles.8 9 HLA alleles can be 
grouped based on their peptide- binding repertoire into 
supertypes.10 Only HLA- A and HLA- B supertypes are well- 
characterized, with Sidney et al (2008) describing nine 
supertypes for HLA- A and HLA- B alleles based on their 
specificity for the anchor amino acids.10
HLA molecule downregulation in cancer tissue is 
a well- established mechanism of cancer evading the 
immune system.11–15 The low expression or low diversity 
of HLA on the cell surface is directly related to the range 
of antigens that can be presented to T cells. Many studies 
have looked at the correlation between expressed HLA- I 
on tumor cells and its effect on survival and response 
to immunotherapy.16–22 However, the effect of low HLA 
genetic diversity (or homozygosity) on response to immu-
notherapy has not been explored, with the exception of 
two recent studies.23 24 Chowell et al investigated the rela-
tionship between genetic HLA homozygosity and survival 
in 100 NSCLC and 269 patients with melanoma treated 
with immunotherapy, either with anti- PD1/PDL1 or anti- 
CTLA4 or both. Reduced survival was correlated with 
homozygosity in at least one HLA- I locus. Therefore, it was 
postulated that maximal heterozygosity of HLAs might 
be associated with higher diversity of antigens presented 
to the T cells, compared with an individual with homo-
zygosity at one or more HLA loci.23 Furthermore, they 
observed that HLA- B62 supertype was strongly associ-
ated with reduced survival, while the HLA- B44 supertype 
associated with longer survival.23 Hence genomic HLA 
can be explored as an economical and easily obtained 
non- invasive biomarker that can help guide treatment 
choice among patients with NSCLC patients treated with 
immunotherapy.
Here, we aim to assess whether homozygosity in HLA- I 
or HLA- II is associated with survival outcomes among 
patients with advanced NSCLC treated with single agent 
anti- programmed cell death protein-1 (PD1) or anti- PDL1 
therapy in the first- line or second- line setting.
METHODS
Patients
Patients were recruited from two major teaching hospi-
tals in Western Australia. Recruited patients were 18 years 
or older, diagnosed with unresectable locally advanced 
NSCLC and treated with single agent pembrolizumab, 
atezolizumab or nivolumab in the first- line or the second- 
line setting. Given that genomic HLA would not be altered 
by infection, treatment or any other environmental 
factors, patients were recruited both prospectively and 
retrospectively. Patient demographics and clinicopatho-
logical features that may affect outcome were collected 
from the clinical records and included: age, Eastern 
Cooperative Oncology Group (ECOG) performance 
status and smoking status. Pre- treatment neutrophil/
lymphocyte ratio (NLR) was calculated using the pre- 
treatment full blood count (FBC) results. Tumor charac-
teristics included: histopathology, PDL1 expression and 
genetic alterations (epidermal growth factor receptor 
(EGFR) mutations, echinoderm microtubule- associated 
protein like-4- anaplastic lymphoma kinase (EML4/ALK) 
fusion, c- ros oncogene 1 (ROS1) fusions and Kirsten RAt 
Sarcoma (KRAS) GTPase mutations). The latter was only 
performed in NSCLC with non- squamous cell carcinoma 
histology.
DNA extraction and genomic HLA-typing
Blood was collected in EDTA blood tubes, and either 
stored as whole blood or white blood cell pellet in a 
freezer at −80°C. QIAamp DNA Blood Maxi Kit was used 
for DNA extraction. Extracted DNA was used for high- 
resolution HLA typing at the Institute of Immunology 
and Infectious disease (IIID) at Murdoch University.
HLA testing at IIID has been accredited by the Amer-
ican Society for Histocompatibility and Immunogenetics 
(ASHI) and the National Association of Testing Authori-
ties (NATA). Specific HLA loci on the extracted DNA are 
PCR amplified using sample- specific molecular indexed 
primers (MID- tagged) that amplify polymorphic exons 
from Class I (A, B, C Exons 2 and 3) and Class II (DQ, 
Exons 2 and 3; DRB and DPB1, Exon 1) HLA genes. MID- 
tagged primers have been optimized to minimize allele 
dropouts and primer bias. Amplified DNA products from 
unique MID- tagged products are pooled in equimolar 
ratios and subjected to library preparation. Post QC and 
quantitation the normalized libraries are then sequenced 
on the Illumina MiSeq platform using the MiSeq V3 600- 
cycle kit (2×300 bp reads). Sequences are separated by 
MID tags and alleles called using an in- house accredited 
HLA allele caller software pipeline that minimizes the 
influence of sequencing errors. Alleles are called using 
the latest IMGT HLA allele database as the allele refer-
ence library. Sample to report integrity was tracked and 
checked using proprietary and accredited Laboratory 
Information and Management System and HLA analyze 
reporting software that performs comprehensive allele 
balance and contamination checks on the final data set.25 
Genomic HLA- A and HLA- B alleles were classified into 
supertypes using the method described by Sidney et al.10
PDL1 analysis
Immunohistochemistry, using the Dako 22C3 clone for 
all patients, for PDL1 testing was performed by PathWest 
Pathology Services as per standard diagnostic services and 
reported as TPS.
Statistical analysis
Progression free survival (PFS) was defined as the time 
interval between the start of therapy and the date of first 
progression/death. Progression was determined by clini-
cian assessment based on both radiological and clinical 
presentation of the patient. Overall survival (OS) was 
defined as the time between the start of immunotherapy 
and death. The minimum follow- up time was 6 months. 
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were still alive at the time of analysis (January 2020) were 
censored.
Patients were dichotomised based on HLA homozy-
gosity at one or more loci and heterozygosity; or based on 
the presence of specific HLA- A and HLA- B supertypes. 
PFS and OS were compared between groups using log- 
rank (Mantel- Cox) test and Kaplan- Meier plots using 
GraphPad Prism V.8 (GraphPad Software, Inc, San Diego, 
California).
A power calculation was carried out assuming a 
frequency of homozygosity in one HLA loci in the general 
population of around 20%, with a median follow- up 
period of 36 months from the time of starting immuno-
therapy, and a median survival for homozygous patients 
of approximately 12 months (based on Chowell et al 
2018 cohort 1).23 If the true HR is 2 for overall survival 
of homozygotes relative heterozygotes, 161 patients will 
be sufficient to reject the null hypothesis with probability 
0.86 and a Type I error probability of 0.05.
Cox regression analyzes were used to compare the effect 
of HLA- I homozygosity on OS outcomes in subgroups 
of patients stratified according to age, sex, PDL1 tumor 
proportion score, pre- treatment NLR, ECOG perfor-
mance scores, smoking status, histopathology, the pres-
ence of KRAS mutations (only among non- squamous cell 
carcinoma (non- SCC) cases), therapy modality and line 
of treatment.
We conducted univariable and multivariable analyzes 
using Cox regression models in SPSS V.25 (IBM, Armonk, 
New York) correlating HLA homozygosity with PFS and 
OS and controlling for tumor PDL1, pre- treatment 
NLR, age, ECOG status and therapy type (anti- PD1 and 
anti- PDL1). As the expression of PDL1 protein on cancer 
cells might be dependent on the first signal of interaction 
between HLA- I molecule on tumor cells and the T- cell 
receptor (TCR), we investigated the interactions between 
HLA homozygosity and tumor PDL1 expression and to 




A total of 170 patients were recruited between May 
2018 and June 2019. Nine patients were excluded: six 
patients were excluded as they were receiving targeted 
therapy or immunotherapy in combination with another 
anticancer agent, one patient died from another cause 
before reaching the response assessment period, and 
two patients were lost to follow- up. A total of 161 patients 
treated with pembrolizumab (n=37), nivolumab (n=72) 
and atezolizumab (n=52) were included in the study. 
Pembrolizumab was administered as first- line therapy, 
while atezolizumab or nivolumab were used as second- 
line or subsequent lines of treatment. Patients’ charac-
teristics and cancer histopathology in the studied cohort 
were similar to the general NSCLC population, with most 
of the patients being smokers (81%), men (56%), more 
than 65 years old (57%) and had good performance 
status (ECOG 0 to 1) (table 1). Adenocarcinoma was the 
predominant lung histology (66%). KRAS mutation was 
the predominant molecular alteration in the non- SCC 
lung cancer, especially in the PDL1 known group. PDL1 
status was available for 114 patients, of whom 61 patients 
(54%) expressed PDL1 in more than 50% of tumor cells. 
Standard of care at the time required that treatment with 
first- line pembrolizumab was only allowed for patients 
with a PDL1 TPS score of ≥50%. Hence, all patients in 







  ≥65 92 (57) 70 (61)
  <65 69 (43) 44 (39)
Sex
  M 90 (56) 66 (58)
  F 71 (44) 48 (42)
ECOG
  ≤1 137 (85) 96 (84)
  >1 23 (14) 17 (15)
  Unknown 2 (1) 1 (1)
Smoking
  Yes 131 (81) 91 (80)
  No 19 (12) 14 (12)
  Unknown 11 (7) 9 (8)
Histopathology
  Adenocarcinoma 106 (66) 74 (65)
  SCC 45 (28) 32 (28)
  Others 10 (6) 8 (7)
Molecular status*
  KRAS mutant 55 (47) 41 (50)
  KRAS wild type 46 (40) 36 (44)
  KRAS unknown 10 (9) 2 (2)
  EGFR, ALK or ROS1 
mutant
5 (4) 3 (4)
Line of treatment
  First line 37 (23) 37 (32)
  Second or more 124 (77) 77 (68)
Total 161 114
*Molecular status was only examined in NSCLC with non- 
squamous cell carcinoma histology (116 patients in full cohort and 
82 in the PDL1 known group).
ALK, echinoderm microtubule- associated protein like-4- anaplastic 
lymphoma kinase (EML4/ALK) fusion; ECOG, Eastern Cooperative 
Oncology Group; EGFR, epidermal growth factor receptor; KRAS, 
Kirsten Rat Sarcoma GTPase; NSCLC, non- small cell lung cancer; 
PDL1, programmed death ligand; ROS1, echinoderm c- ros 
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the PDL1 known group treated with pembrolizumab as 
first- line therapy had their PDL1 expression tested and 
demonstrated ≥50% PDL1 expression in tumor cells. 
Those treated with nivolumab or atezolizumab in the 
second- line setting had TPS scores <50% or were not 
tested for PDL1 expression. This explains the higher 
proportion of first- line therapy patients in the PDL1 
known group. Overall, both groups had very similar char-
acteristics (table 1).
Genomic HLA- I homozygosity at one or more loci 
prevalence was 20%, with a similar proportion (18%) 
observed in the PDL1 group. The prevalence of genomic 
HLA- II homozygosity at one or more loci was moderately 
higher in the PDL1 known group, being 35% compared 
with 33% in the full cohort (online supplemental table 
1). Comparison of clinical characteristics between 
patients with HLA homozygosity and those with maximal 
heterozygosity did not reveal unevenness between groups 
(online supplemental table 2).
Prognostic value of HLA homozygosity
Survival analysis showed that NSCLC patients who were 
treated with single- agent immunotherapy and are homo-
zygous at one or more HLA- I loci had reduced overall 
survival, compared with those who are heterozygous at 
all HLA- I loci (HR=1.96, 95% CI 1.02 to 3.78, p=0.04) 
(figure 1A). The effect of homozygosity at one or more 
HLA- I loci trended towards improved PFS but it was 
not statistically significant (figure 1B). However, we did 
not find a statistically significant effect on OS or PFS, 
when HLA zygosity was evaluated for HLA- A, HLA- B or 
HLA- C separately (data not shown). Moreover, no statis-
tically significant differences were observed in OS or 
PFS between patients that were homozygous at one or 
more HLA- II loci and those that were heterozygous at all 
HLA- II loci (figure 1C,D).
Subgroup analysis suggested that homozygosity at one 
or more HLA- I loci was associated with shorter survival 
especially in patients older than 65, those who have high 
ECOG status (≥2) and those treated with anti- PD1 rather 
than anti- PDL1 immunotherapy (figure 2). In particular, 
HLA homozygosity seemed to significantly affect the 
survival of patients expressing PDL1 in more than 50% 
of their tumor tissue (p<0.001). Kaplan- Meier curves of 
PDL1 status- based subgroups, revealed that the nega-
tive effect of HLA homozygosity on OS and PFS was only 
statistically significant in the subgroup with more than 
50% PDL1- expressing cells, and separation of the curves 
was evident (HR=3.93, 95% CI 1.30 to 11.85, p<0.001) 
(figure 3). The effect of HLA- I zygosity on OS among 
patients with PDL1 ≥50% was driven by homozygosity in 
HLA- A (HR=6.46, 95% CI 1.41 to 29.2, p=0.015, (online 
supplemental figure 1). A very limited number of cases 
Figure 1 Effect of HLA- I/II homozygosity on OS and PFS in patients with NSCLC treated with anti- PD1/PD- L1 immunotherapy. 
A and B, comparison of patients with homozygosity at one or more HLA- I loci on OS and PFS, respectively. C and D, 
comparison of patients with homozygosity at one or more HLA- II loci on OS and PFS, respectively. Kaplan- Meier curves were 
compared using log- rank analysis. HLA,human leukocyte antigen; NSCLC, non- small cell lung cancer; OS, overallsurvival; PD1/
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were found homozygous for HLA- B or HLA- C (n=3 and 
4, respectively), and therefore not suitable for statistical 
analysis. No differences in OS or PFS were observed in 
patients with PDL1 less than 50%, based on their HLA 
genotype.
We carried out univariable and multivariable Cox 
regression analyzes including other variables that may 
affect survival in these patients (age, sex, PDL1 expression, 
ECOG, NLR and therapy type (anti- PD1 and anti- PDL1)) 
(table 2). Homozygosity at one or more HLA- I loci and 
type of checkpoint inhibitor used (anti- PD1 vs anti- PDL1) 
were the only markers associated with OS in the univari-
able analysis (table 2). In the multivariable analysis, NLR 
also emerged as a prognostic marker of OS together 
with treatment type and HLA- I genotype. Notably, after 
controlling for interaction between PDL1 and HLA- I in 
the model, HLA- I homozygosity emerged as having a 
highly significant association with OS (HR=3.70, 95% CI 
1.53 to 8.95, p=0.004). The adverse effect of homozygosity 
at one or more HLA- I loci on PFS was only apparent after 
controlling for interactions between PDL1 status and 
HLA- I genotype (HR=2.18, 95% CI 1.02 to 4.66, p=0.043) 
(table 2). No significant interactions were found between 
HLA- I and the other variables (data not shown).
Prognostic value of HLA-I supertypes
We also investigated the clinical relevance of HLA- I super-
types on patient survival after treatment with anti- PD1/
PDL1 antibodies. Among the eight supertypes evaluated, 
only HLA- A02 had a statistically significant association 
with improved survival (HR=0.56, 95% CI 0.34 to 0.93, 
p=0.023) (table 3, online supplemental figure 1). The 
effect of homozygosity at one or more HLA- I loci among 
PDL1 ≥50% group was driven by the presence of HLA- 
A02 (HR=0.36, 95% CI 0.15 to 0.89, p=0.042) (online 
supplemental figure 2). However, the multivariable anal-
ysis indicated that HLA- A02 status was not an indepen-
dent prognostic variable (online supplemental table 3).
DISCUSSION
Tumor specific markers such as PDL1 expression, tumor 
mutational burden and mismatch repair deficiency have 
been described as predictors of long- term benefit to 
immune checkpoint inhibitor blockade.26 However, varia-
tions in outcomes can also be influenced by host- specific 
factors. Chowell et al 2018 showed in a cohort of mela-
noma and patients with NSCLC treated with single- agent 
anti- PD1 or in combination with anti- CTLA-4, that HLA- I 
homozygosity at one or more loci was associated with 
shorter survival comparing to those who were hetero-
zygous at all HLA- I loci (HR=1.4). However, the study 
did not demonstrate the effect of HLA homozygosity in 
patients with NSCLC specifically. The results of our study 
indicate that homozygosity at one or more HLA- I loci is 
associated with poor outcomes in patients with NSCLC 
treated with single- agent anti- PD1/PDL1 in the first- line 
or the second- line setting.
HLA- I expression in cancer tissue was found to be a key 
factor determining increased immune cell infiltration 
into NSCLC tissue, and independent of PDL1 status.27 
While there is enough evidence to suggest that downreg-
ulation of HLA- I molecule is one of the mechanisms used 
by the tumor to escape the immune system,13 14 a coordi-
nated balance needs to be achieved to avoid destruction 
by natural killer cells (NK cells)28 and this might reduce 
the impact of HLA- I downregulation as a mechanism 
to evade the immune system. On the other hand, loss 
of heterozygosity in cancer tissue was found to be asso-
ciated with poor treatment outcomes.29 30 However, loss 
of genomic heterozygosity in tumor occurs only in 11% 
of cases.23 As shown in our study, germline homozygosity 
of HLA- I at one or more loci also has a clear impact on 
survival, underscoring the role that HLA- I molecules play 
on the immune response against NSCLC.
The effect of HLA- I homozygosity on survival was more 
pronounced in patients with strong PDL1 expression 
Figure 2 Association between HLA- I homozygosity and 
OS. Subgroups were stratified according to age, sex, PDL1 
tumor proportion score, pre- treatment neutrophil- lymphocyte 
ratio (NLR), Eastern Cooperative Oncology Group (ECOG) 
performance scores, smoking status, histopathology, the 
presence of KRAS mutations (only among non- SCC cases), 
therapy modality and line of treatment and analyzed using 
of Cox regression. F,female; HLA,human leukocyte antigen; 
M, male; OS, overall survival; PD1, programmed cell death 
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(≥50%). The expression of PDL1 on tumor tissue, as an 
immune regulatory mechanism has to be preceded by 
an interaction between peptide/HLA- I molecule and 
T cell receptors. This implies that the expressed HLA- I 
molecule is not downregulated in tumor cells and PDL1 
expression is the primary mechanism of immune evasion 
in these cases.27 Therefore, the HLA- I homozygosity may 
have a profound impact on survival among patients with 
PDL1 ≥50%, when treated with PD1/PDL1 inhibitors. 
This also implies that patients with PDL1 <50% utilize 
other immune evasion mechanisms, including downregu-
lation of HLA in cancer cells.
Our results are in contrast with the report by Negrao et 
al,24 which did not find a significant correlation between 
HLA zygosity and survival in an NSCLC cohort treated 
with PD-1/PDL1 at the M. D. Anderson Cancer Center. 
Notably, a large proportion (25%) of their patient cohort 
received anti- PD-1/PDL1 as third- line therapy, while all 
our study participants were treated either in the first- line 
or second- line setting. Moreover, their dichotomisation 
for PDL1 expression was carried out based on 1% TPS, 
while our subgroup analysis was based on a 50% PDL1 
expression cut- off.
Chowell et al showed that the presence of HLA- B62 
and HLA- B44 in patients with melanoma treated with 
immune checkpoint inhibitors are associated with worse 
(HR=2.29) and better prognosis (HR 0.61), respectively. 
However, they did not evaluate the role of HLA supertypes 
in their cohort of patients with NSCLC. In our cohort 
of patients with NSCLC treated with anti- PD1/PDL1 
therapy, the presence of HLA- A02 supertype appears to 
positively affect survival. This may reflect differences in 
cancer biology between melanoma and NSCLC, which is 
reflected by the degree of response to immunotherapy 
and in particular to anti- CTLA4 agents. The differen-
tial effect of HLA supertypes in melanoma and NSCLC, 
may also reflect the differences in the type of mutations 
and therefore neoepitopes between these two cancers.31 
HLA- A02 molecule binds small aliphatic and small hydro-
phobic/aliphatic amino acids in the B and F pockets,10 
for example, KRAS G12V neoantigen represent the 
tumor specific antigen bound to HLA- A*02:01.32 This 
might help predict the type of cancer neoantigens that 
are associated with better survival among patients with 
NSCLC treated with anti- PD1/PDL-1. HLA- B is usually 
expressed more frequently on the cell surface compared 
with HLA- A.33 Nevertheless, the beneficial effects in 
survival outcomes observed for carriers of the HLA- A02 
supertype suggest that NSCLC might escape this down-
regulation mechanism.
Homozygosity at one or more genomic HLA- II loci in 
patients with NSCLC treated with single agent anti- PD1/
Figure 3 Effect of HLA- I homozygosity on survival and progression free survival in patients with NSCLC treated with anti- PD1/
PDL1 immunotherapy based on their PDL1 status (≥50% vs <50%). A and B, association between homozygosity at one or more 
HLA- I loci on OS and PFS, respectively, among patients whom their cancer express PDL1 in ≥50% of the cancer tissue. C and 
D, association between homozygosity at one or more HLA- II loci on OS and PFS, respectively, among patients whom their 
cancer express PDL1 in <50% of the cancer tissue. HLA, human leukocyte antigen; NSCLC, non- small cell lungcancer; OS, 
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PDL1 treatment did not demonstrate a direct influence 
on survival and may require larger numbers to show its 
impact. HLA- II molecule is rarely expressed on cancer 
tissue and more likely expressed on antigen- presenting 
cells.34 Its expression on tumor infiltrating lymphocytes 
rather than NSCLC tissue is associated with better PFS 
and OS.35 HLA- II is responsible for the activation of CD4+ 
helper T- lymphocytes which4 5 then help to activate B- cells 
and CD8+T cells, as well as promote the induction of 
memory CD8+T cell.36 37 The role of CD4+T cells is much 
less understood than CD8+T cells in cancer biology.34 All 
these factors potentially contributed to our observation of 
a lack of statistically significant effect of homozygosity at 
one or more HLA- II molecule on OS and PFS of patients 
with NSCLC treated with single agent anti- PD1/PDL1.
A secondary observation from our analysis was that 
anti- PD1 therapy had longer OS and PFS when compared 
with anti- PDL1 immunotherapy. This observation is 
consistent with the meta- analysis conducted by Tartarone 
et al 2019.38 However, the latter study only carried out 
an indirect comparison and analyzed PFS only. We also 
considered that the results might be largely biased by our 
retrospective cohort, which included a large number of 
long- term survivors who received nivolumab (anti- PD1). 
However, in the absence of an interaction between the 
type of therapy and genomic HLA- I, we believe that this 
finding is unrelated to the main theme of this research 
project.
Our study has some limitations that require discus-
sion. We did not incorporate the role of tumor mutation 
burden (TMB) in this analysis, which is thought to play a 
role in response to immunotherapy.39 However, Chowell 
et al 201823 showed that low TMB among patients with 
melanoma did not predict but that rather had an addi-
tive effect in the prognostic value of genomic HLA- I in 
survival. In addition, we had limited access to cancer 
tissue and were unable to assess somatic loss of HLA- I 
heterozygosity or HLA expression, which have been 
correlated individually with shorter OS and PFS.23 40 For 
some of our patients, a fine needle aspiration (FNA) 
was utilized for assessment of PDL1 status and other 
molecular testing. Limited tissue availability after PDL1 
analysis and other molecular testing is a significant road-
block in the field. In fact, Hurkmans et al40 reported of 
having to exclude 70% of the patients recruited due to 
tissue inadequacy to perform HLA immunohistochem-
istry. Moreover, our study is unable to assess the role of 
homozygosity at one or more HLA- I loci as a predictive 
marker for response to anti- PD1/PDL1 among patients 
with NSCLC. Finally, while our subgroup analysis showed 
a strong association between HLA and survival in patients 
with PDL1 ≥50% TPS, the small number of homozygous 
events resulted in large CIs. Thus, more extensive studies 
are needed to validate the clinical prognosis value of HLA 
zygosity in NSCLC treated with anti- PD1/PDL1 therapy.
Our study provides enough evidence that genomic 
homozygosity is associated with a worse prognosis in 
patients with NSCLC treated with single- agent immuno-
therapy. This is of special importance in NSCLC which 
often relies on FNA for diagnosis, and therefore tumor 
material can be exhausted after performing mutational 
profiling and PDL1 staining. We propose that, in addi-
tion to PDL1 TPS, HLA- I typing should be considered 
as a non- invasive and cost- effective biomarker to guide 
treatment personalisation. Given that patients with HLA- I 
homozygosity are less likely to derive clinical benefit from 
single- agent anti- PD1/PDL1 therapy, consideration of a 
more aggressive treatment combinations may be needed 
to improve their prognosis, especially among those with 
PDL1 TPS of 50% or more.
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Supplementary Table 1: Genomic HLA-I and -II status in the full and PDL1 known cohorts. 
 
Full cohort  
N (%) 
PDL1 known group  
N (%) 
Genomic HLA-I 
  Homozygous at one or more loci 32 (20) 21 (18) 
Heterozygous at all loci 129 (80) 93 (82) 
Genomic HLA-II 
  Homozygous at one or more loci 56 (35) 38 (33) 
Heterozygous at all loci 105 (65) 76 (67) 
Total 161 114 
HLA: Human Leukocyte Antigen 
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Supplementary Table 2: Clinical characteristics of patients by HLA genotype  
 HLA-I P-value HLA-II P-value 
 Homozygous Heterozygous Total 
 
Homozygous Heterozygous Total 
 
Variable N=32  (%) N=129 (%) N=161 (%) N= 56  (%) N= 105 (%) N= 161 (%) 
Age    
 
    
<65 13 (41) 56 (43) 69 (57) 
0.843 
19 (34) 50 (48) 69 (57) 
0.095 ≥65 19 (59) 73 (57) 92 (57) 37 (66) 55 (52) 92 (57) 
Sex         
Female 10 (31) 61 (47) 71 (44) 
0.115 
22 (39) 49 (47) 71 (44) 
0.369 
Male 22 (69) 68 (53) 90 (56) 34 (61) 56 (53) 90 (56) 
Smoking         
Yes 29 (91) 102 (79) 131 (81) 
0.322 
45 (80) 86 (82) 131 (81) 
0.831 
No 2 (6) 17 (13) 19 (12) 7 (13) 12 (11) 19 (12) 
Unk 1 (3) 10 (8) 11 (7)  4 (7) 7 (7) 11 (7)  
ECOG         
1 26 (81) 110 (85) 136 (84) 
0.441 
51 (91) 85 (81) 136 (84) 
0.143 
>1 6 (19) 17 (13) 23 (14) 5 (9) 18 (17) 23 (14) 
Unk 0 2 (2) 2 (1)   2 (2) 2 (1)  
Histopathology         
Adeno 23 (72) 83 (64) 106 (66) 
0.815 
40 (71) 66 (63) 106 (66) 
0.114 
SCC 9 (28) 36 (28) 45 (28) 11 (20) 34 (32) 45 (28) 
Other  0 10 (8) 10 (6)  5 (9) 5 (5) 10 (6)  
NLR         
≥5 14 (44) 47 (36) 61 (38) 
0.464 
21 (38) 40 (38) 61 (38) 
0.905 
<5 18 (56) 81 (63) 99 (61) 35 (62) 64 (61) 99 (61) 
Unk 0 1 (1) 1 (1)  0 1 (1) 1 (1)  
PDL1 status         
≥50% 9 (28) 52 (40) 61 (38) 
0.278 
17 (30.5) 44 (42) 61 (38) 
0.126 
<50% 12 (38) 41 (32) 53 (33) 22 (39) 31 (30) 53 (33) 
Unk 11 (34) 36 (28) 47 (29)  17 (30.5) 30 (28) 47 (29)  
Treatment modality         
Anti-PD1 
(Nivo/Pembro) 
21 (66) 88 (68) 109 (68) 
0.779 
42 (75) 67 (64) 109 (68) 
0.148 
Anti-PDL1 (Atezo) 11 (34) 41 (32) 52 (32) 14 (25) 38 (36) 52 (32) 
Treatment line         
1
st
 line 8 (25) 29 (23) 37 (23) 
0.762 




 line 24 (75) 100 (77) 124 (77) 43 (77) 81 (77) 124 (77) 
KRAS mutant*         
Mutant 13 (57) 42 (45) 55 (47) 
0.974 
22 (49) 33 (46) 55 (47) 
0.217 
Wild-type 11 (48) 35 (38) 46 (40) 13 (29) 33 (46) 46 (40) 
Unk 3 (13) 7 (7) 10 (9)  4 (15) 6 (8) 10 (9)  
Unk – unknown, P-value of Chi-squared test, *KRAS mutation only examined in non-SCC NSCLC (5 patients with 
targetable mutation were excluded from the table), Nivo: nivolumab, Pembro: Pembrolizumab. 
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HLA-A02 (positive vs negative) 0.025 0.56 0.34 0.93 0.242 0.67 0.34 1.31 
Zygosity (hetero vs homo) 0.020 2.17 1.13 4.17 0.046 2.01 1.01 4.00 
Age (<65 vs ≥65 ) 0.534 0.83 0.45 1.51 0.301 0.70 0.36 1.38 
Sex (M vs F) 0.598 1.14 0.69 1.88 0.191 1.53 0.81 2.91 
PDL1  (≥50% vs <50%) 0.916 0.97 0.53 1.77 0.366 0.74 0.39 1.41 
ECOG (≤1 vs ≥2) 0.216 1.63 0.72 3.51 0.201 1.69 0.76 3.76 
NLR (≤5 vs >5) 0.059 1.78 0.98 3.24 0.001 2.97 1.53 5.76 
Therapy type (αPD1 vs αPDL1) <0.001 3.16 1.66 5.99 0.000 4.10 2.02 8.30 
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Supplementary Figure 1: Effect of HLA-A homozygosity on overall and progression-free 
survival in NSCLC patients with PDL1 ≥50% (N=68) treated with anti-PD1/PDL1 
immunotherapy. 
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Supplementary Figure 2: Effect of HLA-A and HLA-B supertypes on overall survival in NSCLC 
patients treated with anti-PD1/PDL1 immunotherapy. 
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Supplementary Figure 3: Effect of the presence of HLA-A02 on OS(A) and PFS(B) in NSCLC 
patients treated with anti-PD1/PDL1 immunotherapy with PDL1 expression ≥50%. 
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